Journal of Chromatography B, 716 (1998) 83–93
On-column formation of arsenic–glutathione species detected by
size-exclusion chromatography in conjunction with arsenic-specific
detectors 1
J. Gailer a , *, W. Lindner b
a
University Department of Molecular and Cellular Biology, The University of Arizona, Life Science South Building, Tucson, AZ 85721,
USA
b
¨ Wien, Wahringerstrasse
¨
33 – 35, 1090 Vienna, Austria
Institute for Analytical Chemistry, Universitat
Received 4 December 1997; received in revised form 28 May 1998; accepted 5 June 1998
Abstract
The ‘retention analysis method’, which is based on size-exclusion chromatography (SEC) in conjunction with an
arsenic-specific detector (graphite furnace atomic absorption spectrometer, GFAAS), was used to study the effect of pH
(range 2.0–10.0), temperature (4, 25 and 378C), and the concentration of glutathione in the mobile phase (0.5–7.5 mM) on
the formation of arsenic–glutathione species after injection of sodium arsenite using phosphate-buffered saline solutions as
mobile phases. The formation of arsenic–GSH species was facilitated by low temperatures (48C), pH 6.0–8.0 and high
concentrations of glutathione (7.5 mM) in the mobile phase. Simulating the physicochemical parameters found inside human
red blood cells (|3.0 mM glutathione, 378C, pH 7.4) and hepatocytes (|7.5 mM glutathione, 378C, pH 7.4), SEC–GFAAS
provided evidence for the formation of arsenic–glutathione species under these conditions. In addition, the ‘chelating agent’,
sodium DL-2,3-dimercapto-1-propanesulfonate (1.0 and 2.0 mM) was demonstrated to bind arsenous acid stronger in the
presence of glutathione (7.5 mM) under these conditions (PBS buffer, pH 7.4, 378C). 1998 Elsevier Science B.V. All
rights reserved.
Keywords: Arsenite; Glutathione
1. Introduction
The tripeptide glutathione (GSH) ( L-g-glutamyl-Lcysteinyl-glycine), which is present in a large variety
of mammalian cells at concentrations ranging from
*Corresponding author.
1
Part of this work was carried out at the Institute for Analytical
¨ Graz, 8010 Graz, Austria.
Chemistry, Karl-Franzens Universitat
0.1 to 10 mM, is the most prevalent intracellular thiol
in mammals [1]. Two human cell types have particularly high intracellular GSH concentrations: red
blood cells (|3.0 mM GSH) [2] and hepatocytes
(|7.5 mM GSH) [3]. Although other thiols, such as
L-cysteine, ergothioneine and hemoglobin can also
be present in certain mammalian cells, their concentrations are often negligible compared to the
concentration of GSH. In hepatocytes, for instance,
the concentration of L-cysteine is 0.2–0.5 mM and,
0378-4347 / 98 / $19.00 1998 Elsevier Science B.V. All rights reserved.
PII: S0378-4347( 98 )00282-5
84
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
hence, an order of magnitude lower than that of GSH
[4].
Because of the generally high affinity of thiols for
metal ions, such as Zn 21 , Cd 21 , Pb 21 , Hg 21 ,
CH 3 Hg 1 , Cu 21 , Fe 21 , Cr 31 , Pt 21 , Ni 21 , Co 21 and
Ag 1 , and for metalloid compounds, such as arsenous
acid, numerous metal / metalloid–GSH complexes
have been detected intracellularly by noninvasive 1 H
spin-echo Fourier transform (SEFT)–NMR spectroscopy [5,6]. In addition, matrix assisted laser desorption / ionization mass spectroscopy (MALDI) has
been utilized to detect arsenic / antimony–
trypanothione adducts [7]. Because metal–GSH
complexes are involved in the uptake and excretion
of several metal ions in mammals [8,9], the detection
of metal–GSH complexes is of high interest for
understanding the metabolism of trace metals / metalloids. Conversely, metal / metalloid–GSH complexes
can seriously affect the cellular metabolism of GSH
[10–12].
Chromatographic techniques in conjunction with
radio or element-specific detectors have also been
employed to detect metal–GSH complexes in biological fluids [13–15]. However, the main difficulty
using this technique is that the metal, complexed on
a certain binding site of GSH, can be released easily,
depending on the equilibrium constant [5,16]. Consequently, labile metal / metalloid–GSH complexes
cannot be detected directly by conventional chromatographic techniques because they dissociate during the chromatographic process. This undesirable
situation can be remedied by the ‘retention analysis
method’, a chromatographic method based on sizeexclusion chromatography (SEC), which was introduced in 1980 to study reversible associations between drugs, such as warfarin or furosemide, and
human serum albumin under simulated physiological
conditions [17]. Generally, an increase of the albumin concentration in the mobile phase causes a
decrease in the retention time of the drug [18,19],
provided that the drug–albumin associate formed is
excluded from the size-exclusion matrix. Hence, any
reduction in the retention time of a drug when
albumin is added to the mobile phase indicates the
formation of a drug–albumin associate.
This work examines the formation of arsenic–
GSH species in phosphate-buffered saline (PBS)
buffers applying the ‘retention analysis method’
using SEC (Sephadex G-10) in conjunction with
graphite furnace atomic absorption spectrometry
(GFAAS) or radiodetection of 73 As as the arsenicspecific detector. The influence of the temperature,
the pH, the concentration of GSH and the presence
of sodium DL-2,3-dimercapto-1-propanesulfonate
(DMPS) in the PBS buffer on the formation of
arsenic–GSH species was studied.
2. Experimental
2.1. Chemicals
NiSO 4 ?6H 2 O and NaAsO 2 , both of p.a. quality,
NaCl, Na 2 HPO 4 ?7H 2 O, KCl, KH 2 PO 4 , glutathione
(GSH) .98% and Nesslers reagent were purchased
from Merck (Darmstadt, Germany). Sodium DL-2,3dimercapto-1-propansulfonate (DMPS) (95%) was
purchased from Aldrich (Milwaukee, WI, USA),
5,59-Dithiobis(2-nitro-benzoic acid) (DTNB) was
purchased from Fluka (Buchs, Switzerland) and
Sephadex G-10 was purchased from Pharmacia
(Uppsala, Sweden). A solution of 73 AsV in conc.
hydrochloric acid with a specific activity of 1.62
mCi / ml was purchased from Los Alamos Laboratory
(Los Alamos, NM, USA). All other chemicals were
of the highest purity.
2.2. Size-exclusion chromatography
A Pharmacia thermostatable XK-26 gel-chromatography column (7032.6 cm) was filled with
Sephadex G-10 to a final height of 63 cm. Similarly,
a Pharmacia thermostatable XK-16 gel-chromatography column (7031.6 cm) was filled with Sephadex
G-10 to a final height of 60 cm. The temperature of
both columns was kept at the desired temperature
using a Lauda RC6 thermostat. The flow-rate was
maintained either at 0.5 or 0.6 ml / min with a
peristaltic pump. The PBS buffer was prepared by
dissolving 40.0 g of NaCl, 13.6 g of Na 2 HPO 4 ?
7H 2 O, 1.0 g of KCl and 1.2 g of KH 2 PO 4 in triply
distilled water and the volume was adjusted to the 5-l
mark. The PBS buffer was degassed with a water
aspirator for 10 min before use. After the addition of
either GSH or GSH and DMPS to the degassed PBS
buffer, the pH was adjusted to pH 2.0, 3.0, 4.0, 5.0,
6.0, 7.0, 7.4, 8.0, 9.0 or 10.0 by the dropwise
addition of either conc. HCl or 2.0 M NaOH using
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
an Orion SA 720 pH meter. To prevent the oxidation
of GSH by oxygen from air during storage, the PBS
buffers containing GSH and / or DMPS were prepared freshly for each chromatographic run. The
PBS buffers with pH.7.4 were continuously flushed
with nitrogen during the whole chromatographic
process to prevent oxidation of GSH. The Sephadex
G-10 column with a diameter of 2.6 cm was equilibrated with at least 200 ml and the G-10 column
with a diameter of 1.6 cm was equilibrated with at
least 100 ml of mobile phase before an aqueous
solution of sodium arsenite was injected.
With the 2.6 cm-diameter Sephadex G-10 column,
5-ml fractions were collected, and with the 1.6 cmdiameter Sephadex G-10 column, 2-ml fractions
were collected, using a FRAC 300 fraction collector
(Pharmacia). The exclusion volume, which was
determined by injection of 0.3 ml of an aqueous
solution of blue dextran, was 115 ml (fraction 23)
for the 2.6 cm-diameter column and 40 ml (fraction
20) for the 1.6 cm-diameter column. The 2.6 cmdiameter Sephadex G-10 column (fractionation range
up to a molecular mass of 700) was roughly calibrated with oxidized glutathione, GSSG (molecular
mass, 612), GSH (molecular mass, 307), glycine
(molecular mass, 75) and NH 1
4 ions (molecular mass,
17). GSSG was detected in the individual fractions
by UV detection at 212 nm. GSH was detected
visually in the fractions after the addition of 100 ml
of a methanolic DTNB solution (200 mg of DTNB
in 50 ml of methanol). NH 1
was also visually
4
detected in the fractions after the addition of 0.5 ml
of Nesslers reagent to each fraction. Glycine was
detected visually after the addition of 100 ml of a
methanolic ninhydrin solution (100 mg of ninhydrin
in 5.0 ml of methanol) to each fraction.
Aliquots (0.3 ml) of a sodium arsenite stock
solution (100 mg As / l, 1.3 mM) or aliquots (0.22
ml) of a solution of radiolabeled Na 73 AsO 2 (0.29
mCi / ml), both containing 30 mg of total arsenic,
were injected onto both columns and fractions were
collected. Every chromatogram was carried out in
duplicate.
2.3. Graphite furnace atomic absorption
spectrometric determination of arsenic
A Hitachi Z-9000 Zeeman graphite furnace atomic
absorption spectrometer (GFAAS) equipped with an
85
arsenic hollow cathode lamp (S&J Juniper, Essex,
UK), operated at 10 mA, was used to determine
arsenic (193.7 nm) in the collected fractions.
Graphite cuvettes (Ringsdorff Werke, Bonn, Germany) of the highest purity graphite (type RWO,
shape RWO 521) and argon (99.999%) were used.
Direct determination of arsenic in PBS buffer by
GFAAS was impossible because of the high background absorption signal produced by the high salt
concentration of the PBS buffer (|10 g / l) during
atomization. Hence, the PBS buffer was diluted 1:10
(v / v) with triply distilled water to allow background
correction of the arsenic signal. Because nickel salts
enhance the GFAAS signal for arsenic and, therefore, increase the signal-to-noise ratio [20], nickel
sulfate was used as a coanalyte. To 1.0 ml of the
collected fraction (PBS buffer), 80 ml of a 2.0-M
nickel sulfate solution were added and the obtained
solution was filled to the 10-ml mark with triply
distilled water. Aliquots of this solution (20 ml) were
subsequently injected into the GFAAS, dried at
temperatures rising from 50 to 2008C within 5 s, kept
at 2008C for 20 s, ashed at 3008C for 5 s, and
atomized at 26008C for 5 s. The cuvette was then
cleaned at 30008C for 3 s. The calibration curve for
arsenic was linear up to 0.3 AU and the detection
limit (5 s) for arsenic was 70 mg As / l in PBS buffer.
The recovery of arsenic in the fractions was always
better than 80%.
2.4. Radiodetection of
73
As
An aliquot (20 ml) of the purchased 73 AsV solution
was reduced to 73 As III according to Reay and Asher
[21]. After the addition of ‘cold’ sodium arsenite and
sodium arsenate, the obtained solution was passed
over a QAE Sephadex A 25 column (3031.6 cm)
using PBS buffer as the mobile phase. Residual
73
AsV was strongly retained by the column, whereas
73
As III eluted in a single peak. The peak fractions
corresponding to 73 As III were pooled. The concentration of the radiolabeled 73 As III solution was 136
mg As / ml and corresponded to 53 200 cpm. Aliquots
(0.22 ml) of this solution were injected onto the 1.6
cm-diameter Sephadex G-10 column. Radiolabeled
arsenic was detected in the individual fractions by
counting each whole fraction (2 ml) for 60 s in a
gamma counter (1282 Compugamma universal
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
86
gamma counter, LKB Wallac, MD, USA). The
recovery of 73 As in the fractions was always .87%.
3. Results and discussion
Although considerable knowledge about the mammalian metabolism of arsenous acid has been accumulated, strikingly little is known about the molecular form of arsenic inside mammalian cells. In
hepatocytes, the major site of arsenous acid biotransformation, the most prevalent low-molecularmass thiol is GSH. Because arsenous acid has a high
affinity for thiols [22,23], the intracellular reaction
between arsenous acid and GSH could yield arsenic–
GSH species. Arsenous acid with a pK1 of 9.2 is
present as undissociated As(OH) 3 at pH 7.4, the pH
inside mammalian liver cells [24]. At this pH, GSH
has both carboxyl groups completely deprotonated
(pKCOOH 1 52.1; pKCOOH 2 53.5), the amino group
protonated (pKNH2 59.6), and 2.8% of the sulfhydryl
groups ionized [25]. Because arsenous acid has three
OH groups, it could in principle react with one, two
or three GSH molecules, giving rise to GS–As(OH) 2
(molecular mass, 415), (GS) 2 As–OH (molecular
mass, 704) or (GS) 3 As (molecular mass, 993). Scott
et al. [26] titrated a solution of arsenous acid in 0.5
M potassium phosphate buffer solution (pH 7.1 in
D 2 O) with a solution of GSH and monitored the
methine (Cys a) and methylene (Cys b) protons of
1
glutathione by H-NMR, compared to an aqueous
GSH solution. Because of a large chemical shift of
the methylene protons (Cys b) and a smaller shift of
the methine protons (Cys a) upon addition to the
arsenous acid, they concluded that binding of arsenous acid to the thiol group of GSH had occurred.
Because signals corresponding to excess GSH were
detected only after the molar ratio of GSH–arsenous
acid had reached 3.5, they postulated that the stoichiometry of the formed arsenic–GSH species was
(GS) 3 As (Eq. (1); x53).
H 2O
As(OH) 3 1 xGSH á (GS) x 2 As(OH) 32x 1 xH 2 O
x 51,2,3
(1)
We used a chromatographic technique, i.e. the
‘retention analysis method’, to study the reaction
between arsenous acid and GSH in PBS buffers
using SEC coupled off-line to either GFAAS or the
radiodetection of 73 As. Because any attempts to
characterize the detected product(s) of the reactions
between arsenous acid and GSH, and between arsenous acid, GSH and DMPS, by mass spectroscopy
fractions failed (presumably because of the PBS
buffer matrix and the large excess of GSH), the term
‘arsenic–GSH species’ will be used in the following
discussion. The term ‘arsenic–GSH species’ does not
provide information about how many GSH molecules are bound to the arsenic atom and may even
refer to mixtures of molecules with one, two or three
GSH molecules bound to the arsenic atom.
3.1. Influence of the GSH concentration,
temperature and the pH of the PBS buffer on the
formation of arsenic–GSH species
3.1.1. Influence of the GSH concentration in the
PBS buffer at 48 C
Separate injections of blue dextran, GSSG, GSH,
NH 1
ions and glycine showed that the column
4
separates these molecules presumably according to
their molecular mass (Fig. 1a). The smallest molecule injected onto the column, the NH 1
4 ion, eluted
in fractions 41–47 (glycine also eluted in this
fraction range). Surprisingly, arsenous acid, with a
molecular mass of 126 (which should elute before
the NH 1
ion and should, hence, be present in
4
fractions prior to number 40) was detected in fractions 53–66 (Fig. 1a). This suggests that, apart from
the size-exclusion mechanism, another, as yet unspecified, chemical interaction occurs between arsenous acid and the Sephadex G-10 matrix. Sephadex is
a bead-formed gel prepared by crosslinking dextran
with epichlorhydrin. The free hydroxyl groups of the
dextran in the Sephadex G-10 gel probably interact
with the OH groups of arsenous acid via hydrogen
bonds and, hence, retard the migration of arsenous
acid through the column. Two of the three possible
products of the reaction of arsenous acid with GSH,
namely GS–As(OH) 2 and (GS) 2 As–OH, also have
OH groups that could interact with the hydroxyl
groups of dextran, as arsenous acid does with three
hydroxyl groups. Because these interactions may
also occur, the exact molecular masses of the de-
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
Fig. 1. Chromatograms obtained at 48C after the injection of 30
mg of arsenic, as sodium arsenite. Column, Sephadex G-10 (633
2.6 cm); mobile phase, PBS buffer (151 mM, pH 7.4) and PBS
buffers with GSH concentrations ranging between 0.5 and 7.5
mM, adjusted to pH 7.4; injection volume, 0.3 ml; flow-rate, 0.6
ml / min; fraction volume, 5.0 ml; arsenic-specific detector,
GFAAS at 193.7 nm. Abbreviations: GSSG, oxidized glutathione;
MM, molecular mass; Gly, glycine.
tected arsenic–GSH species (Fig. 1b–g) cannot be
deduced.
When arsenous acid was chromatographed with a
0.5-mM solution of GSH in PBS buffer (adjusted to
pH 7.4), arsenic was detected in fractions 41–66
(Fig. 1b). The major arsenic peak (fractions 53–66)
corresponds to unchanged arsenous acid, because it
covers the same fraction range as found for arsenous
acid with PBS buffer alone (Fig. 1a). However,
arsenic, at low concentrations, was also present in
87
fractions 41–53 (Fig. 1b). This experimental fact can
be rationalized by the presence of an arsenic–GSH
species with a larger molecular mass than that of
arsenous acid. After the injection of arsenous acid
onto the column, a portion of the arsenous acid very
likely forms an arsenic–GSH species of larger
molecular mass than arsenous acid, which migrates
faster than arsenous acid because it is excluded from
the gel. This should cause the arsenic signal to tail
towards smaller fraction numbers, as observed. Probably because of hydrolysis, the arsenic–GSH species
then fall apart, and arsenous acid once again reacts
with GSH to form arsenic–GSH species, and so on.
Hence, the formation of arsenic–GSH species followed by rapid hydrolysis could explain the observed
peak shape in Fig. 1b.
Chromatography of arsenite with 1.0 or 1.5 mM
solutions of GSH in PBS buffer brought about a
more pronounced shift in the elution of arsenic
towards the exclusion volume (Fig. 1c–d). With the
1.0 mM solution of GSH in PBS buffer, the major
arsenic peak covered fractions 29–47 (peak maximum: fraction 33). However, the peak still showed
considerable tailing (Fig. 1c). With the 1.5 mM
solution of GSH in PBS buffer, arsenic eluted in a
distinct band (fractions 29–42; peak maximum:
fraction 32) and exhibited only minor tailing (Fig.
1d).
With 2.5 mM GSH in the PBS buffer, arsenic
eluted in fractions 27–41 (peak maximum: fraction
28) (Fig. 1e). This indicates that an even larger
molecular mass arsenic–GSH species is formed
under these conditions, compared to those found in
the 1.0 and 1.5 mM solutions of GSH in PBS buffer.
A further increase of the GSH concentration in the
PBS buffer, to 5.0 and 7.5 mM, shifted the elution of
arsenic to the exclusion volume (fraction 23) (Fig.
1f–g). The chromatograms obtained with 5.0 and 7.5
mM GSH are very similar. With the 7.5 mM GSH
PBS buffer, arsenic eluted in a narrow band covering
fractions 23–28 (Fig. 1g). Because Sephadex G–10
fractionates molecules up to a molecular mass of
700, which corresponds to fraction 23, the arsenic–
GSH species detected under these conditions may be
tentatively characterized with a molecular mass of
$700 [(GS) 3 As with a molecular mass of 994 and /
or (GS) 2 As–OH with a molecular mass of 704].
These results clearly indicate that an increase in
88
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
the concentration of GSH in the mobile phase shifts
the elution of arsenic from the small-molecular-mass
region towards the large-molecular-mass region. This
can be rationalized by the formation of arsenic–GSH
species that have a larger molecular mass than
arsenous acid and are, hence, excluded from the gel.
An increase of the GSH concentration of the mobile
phase consequently shifts the chemical equilibrium
in Eq. (1) to the right.
3.1.2. Influence of the temperature of the PBS
buffer at 2.5, 5.0 and 7.5 mM GSH
The effect of temperature on the formation of
arsenic–GSH species was investigated at physiologically relevant concentrations of GSH in PBS buffer.
An increase of the temperature from 4 to 378C did
not change the elution volume of blue dextran,
GSSG, GSH and NH 1
4 injected onto the column.
Hence, the observed retention shifts cannot be
caused by an altered pore size of the Sephadex G-10
matrix.
3.1.2.1. 2.5 mM GSH in PBS buffer. With a 2.5-mM
solution of GSH in PBS buffer, arsenous acid was
chromatographed on a Sephadex G-10 column at 4,
25 and 378C (Fig. 2a–d). At 48C, arsenic was
detected in a band covering fractions 27–41, indicating that arsenic–GSH species had been formed under
these conditions (Fig. 2a).
At 258C, arsenic eluted in fractions 27–38 and
fractions 49–53 (Fig. 2b). Both peaks contained
similar amounts of total arsenic. The first band
corresponds to the same fraction range as observed at
48C (Fig. 2a).
At 378C, arsenic eluted in a single band covering
fractions 52–59 (Fig. 2c). Because arsenic was
detected in fractions 57–66 when arsenous acid was
chromatographed with PBS buffer alone at 378C
(Fig. 2d), a weak association of arsenous acid and
GSH must occur under these conditions. Because
these conditions resemble the physicochemical conditions in human red blood cells (PBS buffer, |3.0
mM GSH, pH 7.4, 378C), a weak association of
arsenous acid with GSH possibly also occurs in these
cells in vivo.
This finding is in accord with results obtained by
1
H-spin echo NMR with rabbit red blood cells (|2.8
mM GSH) [6]. Intracellular binding of arsenous acid
Fig. 2. Chromatograms obtained after the injection of 30 mg of
arsenic, as arsenous acid, at 4, 25 and 378C. Column, Sephadex
G-10 (6332.6 cm); mobile phase: 2.5 mM GSH in PBS buffer
(151 mM), adjusted to pH 7.4, and PBS buffer (151 mM, pH 7.4);
injection volume: 0.3 ml; flow-rate, 0.6 ml / min; fraction volume,
5.0 ml; arsenic-specific detector, GFAAS at 193.7 nm.
to GSH was observed after the addition of arsenous
acid to the extracellular medium. Exposure of red
blood cells to 14 C-labeled phenyldichloroarsine resulted in the intracellular formation of a 1:2 adduct
with intracellular GSH [27]. Evidence for the formation of mixed complexes of arsenous acid with GSH
and hemoglobin in red blood cells has also been
reported [28].
3.1.2.2. 5.0 mM GSH in PBS buffer. The chromatograms obtained with arsenous acid on a Sephadex
G-10 column and with a PBS buffer containing 5.0
mM GSH at 4, 25 and 378C are shown in Fig. 3a–c.
At 48C, arsenic was detected in fractions 24–32, with
the highest arsenic concentration being detected in
fraction 26 (Fig. 3a).
Chromatography of arsenous acid at 258C resulted
in the elution of arsenic in a double peak (Fig. 3b).
The first peak (fractions 25–37) showed considerable tailing and had a second, relatively sharp peak
superimposed on its long retention end (fractions
37–42).
At 378C, arsenic eluted in two sharp, distinct
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
89
Fig. 3. Chromatograms obtained after injection of 30 mg of
arsenic, as arsenous acid, at 4, 25 and 378C. Column, Sephadex
G-10 (6.332.6 cm); mobile phase, 5.0 mM GSH in PBS buffer
(151 mM), adjusted to pH 7.4; injection volume, 0.3 ml; flow-rate,
0.6 ml / min; fraction volume, 5.0 ml; arsenic-specific detector,
GFAAS at 193.7 nm.
Fig. 4. Chromatograms obtained after injection of 30 mg of
arsenic, as arsenous acid, at 4, 25 and 378C. Column, Sephadex
G-10 (6.332.6 cm); mobile phase, PBS buffer (151 mM) with 7.5
mM GSH, adjusted to pH 7.4; injection volume, 0.3 ml; flow-rate,
0.6 ml / min; fraction volume, 5.0 ml; arsenic-specific detector,
GFAAS at 193.7 nm.
peaks covering fractions 27–32 and 47–52, respectively (Fig. 3c).
to arsenous acid [29–31]. These reports also claim
that arsenic–GSH species are involved in the excretion of arsenous acid across the liver / bile barrier,
which is mediated by ATP-dependent glutathione
S-conjugate (GS-X) pumps located at the canalicular
site of hepatocytes plasma membranes [32]. Because
these GS-X pumps generally exhibit a broad substrate specificity towards different types of glutathione S-conjugates [32,33], arsenic-GSH species
could also be substrates for these pumps. The first
direct experimental evidence that arsenic-GSH
species are the active species pumped across the
¨
liver / bile barrier has been reported by Muller
et al.
[34], who showed that, in TR2 rats, i.e. transgenic
rats with inactive GS-X pumps in their hepatocytes,
the excretion of arsenous acid and GSH is abolished.
In addition, Dey et al. [35] demonstrated an ATPdependent arsenic–GSH transport system in membrane vesicles of Leishmania tarentolae. Hence,
arsenic–GSH species are involved in the excretion of
arsenous acid and may also be involved in drug
resistance.
3.1.2.3. 7.5 mM GSH in the PBS buffer. The chromatograms obtained with arsenous acid on a
Sephadex G-10 column using a PBS buffer containing 7.5 mM GSH at 4, 25 and 378C are shown in
Fig. 4a–c. At 48C, arsenic eluted in a sharp peak
covering fractions 23–28 (Fig. 4a). At 258C, arsenic
eluted in a broader peak than at 48C, covering
fractions 24–32 (Fig. 4b). When arsenous acid was
chromatographed at 378C, arsenic was detected in
fractions 25–35 (Fig. 4c). Because these conditions
(7.5 mM GSH, pH 7.4, 378C) resemble those of
human hepatocytes, our results suggest that arsenous
acid possibly binds to GSH in vivo.
These results indicate that the equilibrium in Eq.
(1) is strongly affected by temperature changes in
the range 4–378C. An increase in temperature shifts
the equilibrium to the left. Hence, arsenic–GSH
species are rather labile at ambient temperature, a
finding that is in accord with other reports
[23,27,29]. The detection of arsenic–GSH species at
simulated physiological conditions (378C, pH 7.4,
2.5–7.5 mM GSH in PBS buffer) substantiates
indirect experimental evidence for the formation of
arsenic–GSH species in the liver of animals exposed
3.1.3. Influence of the pH of the PBS buffer
To determine the influence of pH on the oncolumn formation of arsenic–GSH species, arsenous
acid was chromatographed on a 1.6-cm-diameter
90
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
Sephadex G-10 column with PBS buffers containing
5.0 mM GSH and with the pH adjusted to values
between 2.0 and 10.0 at 48C. The chromatograms are
summarized in Fig. 5.
At pH values of 2.0 and 3.0, arsenic was detected
in fractions 21–64 (peak maximum: fraction 53)
(Fig. 5a). The major arsenic peak (fractions 48–64,
86% of total As) covers the same fraction range as
arsenous acid with PBS buffer alone (fraction 43–
65) and, hence, corresponds to unchanged arsenous
Fig. 5. Chromatograms obtained at 48C after injection of 30 mg of
arsenic, as 73 As labeled arsenous acid, at pH values between 2.0
and 10.0. Column, Sephadex G-10 (6231.6 cm); mobile phase,
5.0 mM GSH in PBS buffer (151 mM), adjusted to the desired
pH; injection volume, 0.22 ml; flow-rate, 0.5 ml / min; fraction
volume, 2.0 ml; arsenic-specific detection of 73 As by gammacounting, 5 mg As corresponds to 1950 cpm.
acid. However, a small fraction of the arsenic (14%)
elutes in the fraction range of arsenic–GSH species.
At pH 4.0, arsenic eluted in fractions 20–61 (peak
maximum: fraction 52) (Fig. 5b). The major arsenic
peak (fraction 46–61) contained 65% of the total
arsenic. The arsenic that eluted in fractions 20–45
indicates the presence of arsenic–GSH species.
At pH 5.0, arsenic covered the fraction range
20–63 (peak maximum: fraction 23) (Fig. 5c). The
major arsenic peak (fraction 20–44) accounted for
63% of the total arsenic and had a minor arsenic
peak sitting on its long retention end (fractions
45–63).
Chromatography of arsenous acid at pH values of
6.0, 7.0 and 8.0 produced only one arsenic band that
eluted in fractions 20–38 (Fig. 5d–e). Because this
peak accounts for more than 90% of the injected
dose, and because no arsenic was detected in larger
fraction numbers, arsenic is present entirely as an
arsenic–GSH species at these pH values.
A further increase of the pH to 9.0 shifted the
elution of arsenic to fractions 35–52 (Fig. 5f). At pH
10, arsenic was quantitatively recovered in fractions
49–65 (Fig. 5g), which corresponds to the fraction
range found for the elution of arsenous acid with
PBS buffer at this pH alone (data not shown).
All attempts to chromatograph the arsenic–GSH
species, prepared by mixing 30 mg of radiolabeled
As III (0.22 ml) with a stoichiometric amount of GSH
(3 mol equivalents), with PBS buffers, pH 2.0 and
7.0, failed to detect an arsenic peak in the fraction
range corresponding to that for arsenic–GSH species
(fractions 20–40). Hence, arsenic–GSH species are
labile and fall apart during the chromatographic
process.
In the observed pH range, i.e. pH 2.0 and 10.0,
arsenic–GSH species were detected in the pH range
between 2.0 and 8.0. These findings are generally in
accord with results by Delnomdedieu et al. [36], who
reported arsenic–GSH species to be stable between
pH 1.5 and 7.5. They used the 13 C-chemical shift of
the methylene (Cys b) and methine (Cys a) carbon
atoms as a measure of the binding of arsenous acid
to GSH. However, in our experiments, the detection
of only arsenic–GSH species (without free arsenous
acid) was restricted to the pH range between 6.0 and
8.0. This apparent contradiction of Delnomdedieu’s
data may be because 13 C-NMR provides a static
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
91
picture of the solution chemistry, whereas the results
obtained by SEC in conjunction with radiodetection
of 73 As provide a dynamic picture of the chemical
reactions involved. Hence, our experiments indicate
that a decrease in the pH of the mobile phase from
pH 7.0 to 2.0 shifts the equilibrium in Eq. (1) to the
left.
3.2. Influence of sodium DL-2,3 -dimercapto-1 propanesulfonate on the formation of arsenic–GSH
species
The ‘retention analysis method’ can be ideally
applied to the study of competitive interactions
between arsenous acid, monothiols (GSH) and
dithiols (DMPS). The ‘chelating agent’, DMPS, is an
orally effective drug for mobilizing heavy metals,
such as mercury and arsenic, from the bodies of
patients suffering from arsenic / mercury intoxication
[37,38]. We therefore studied the effect of DMPS on
the formation of arsenic–GSH species under simulated physiological conditions (PBS buffer, pH 7.4,
378C).
After the injection of arsenous acid onto a
Sephadex G-10 column equilibrated with a PBS
buffer containing 7.5 mM GSH at 378C, arsenic
eluted in fractions 25–35 (Fig. 6a), suggesting the
presence of arsenic–GSH species. When arsenous
acid was chromatographed with a PBS buffer containing 7.5 mM GSH and 1.0 mM DMPS (pH 7.4,
378C), arsenic was detected in fractions 40–50 (Fig.
6b). Arsenic eluted in fractions 44–53 when a PBS
buffer containing 7.5 mM GSH and 2.0 mM DMPS
(pH 7.4, 378C) was used to chromatograph arsenous
acid (Fig. 6c). With 1.0 mM DMPS in PBS buffer
alone, arsenic eluted in fractions 71–90 (Fig. 6d).
Because arsenous acid eluted in fractions 56–64 at
378C with PBS buffer alone (data not shown), an
interaction between the formed arsenic–DMPS adduct and the free hydroxyl groups of the Sephadex
G-10 gel does occur.
Compared to the elution of arsenic with PBS
buffer with GSH alone (7.5 mM), the addition of
DMPS (1.0 and 2.0 mM) to this buffer shifted the
elution of arsenic to higher fraction numbers (Fig.
6a–c). This shift can be rationalized by the formation
of an arsenic–DMPS adduct that is more stable than
the arsenic–GSH species under these conditions.
Fig. 6. Chromatograms obtained at 378C after injection of 30 mg
of arsenic, as arsenous acid, using PBS buffers containing GSH
and / or DMPS. Column, Sephadex G-10 (6232.6 cm); injection
volume, 0.3 ml; flow-rate, 0.6 ml / min; fraction volume, 5.0 ml;
arsenic-specific detector, GFAAS at 193.7 nm.
The observed shift in the retention of arsenic after
the addition of DMPS may be caused by a smaller
molecular mass of the formed arsenic–DMPS adduct. According to Dill et al. [39], who reported a
six-membered heteroadduct between lipoic acid (6,8dithiooctanoic acid) and phenyldichlorarsine, a fivemembered heteroadduct between DMPS and arsenous acid is most likely formed in solution:
This adduct has recently been detected in aqueous
solution (data not shown) and has a molecular mass
of 277. This is considerably smaller than the molecular mass of (GS) 3 As (994) and, thus, could account
for the observed retention shift from the large to the
small molecular mass fraction range.
Because of the observed interaction of the arsenic–DMPS adduct with the Sephadex G-10 column
92
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
with PBS buffer alone (Fig. 6d), the observed
retention shift of arsenous acid upon addition of
DMPS could also be explained by this interaction.
Which of these two mechanisms (probably both)
caused the observed retention shift cannot be deduced on the basis of these observations. In either
case, however, stronger binding of arsenous acid to
DMPS than to GSH is evident. This experimental
finding is in good agreement with results reported
elsewhere [40,41]. Experiments are underway to
purify and to characterize an arsenic–DMPS adduct.
3.3. Advantages and disadvantages of SEC–
GFAAS
SEC–GFAAS offers several advantages compared
to noninvasive 1 H SEFT–NMR spectroscopy for
studying metal / metalloid–peptide interactions. For
instance, SEC–GFAAS can be used to simulate
reactions at physiological temperatures and physiological metal / metalloid concentrations, which may
be a problem with 1 H SEFT–NMR spectroscopy
because of linebroadening phenomena at high temperatures and a lack of sensitivity. Like 1 H SEFT–
NMR spectroscopy, SEC–GFAAS allows one to
study competitive interactions concerning molecules
dissolved in the mobile phase (GSH and / or DMPS).
However, the utilization of SEC–GFAAS has also
some inherent drawbacks. Because the detection of
the metal / metalloid–peptide species is performed
with an excess of the peptide (GSH) in the mobile
phase, no complex formation constant for the metal /
metalloid–peptide species can be calculated. In
addition, the excess peptide (GSH) may also drastically impede the molecular characterization of the
metal / metalloid–peptide complex formed by e.g.
MALDI–TOF. Unknown interactions between the
metal / metalloid and the Sephadex gel matrix do
occur and SEC–GFAAS does not provide information about the specific binding site on the peptide
(GSH).
arsenic–GSH species in PBS buffer under various
physicochemical conditions. The formation of arsenic–GSH species was facilitated at high concentrations of GSH (7.5 mM) in the mobile phase and
low temperatures in the observed temperature range
(4–378C). At 48C, the formation of arsenic–GSH
species was detected at pH values of between 2.0
and 8.0, with arsenic–GSH species being the only
species formed between pH values of 6.0 and 8.0.
These results, together with the inability to detect
arsenic–GSH species in the corresponding fraction
range after injection of a mixture of arsenous acid
(30 mg As) and GSH (370 mg) with PBS buffers
without GSH in the pH range 2.0–7.0 at 48C clearly
indicate that arsenic–GSH species are labile.
Simulating the intracellular physiological parameters found inside human red blood cells (2.5 mM
GSH, pH 7.4, 378C) and hepatocytes (7.5 mM GSH,
pH 7.4, 378C) with the mobile phase demonstrated
that arsenic–GSH species can be formed under these
conditions. Together with NMR investigations,
which demonstrated that arsenic binds to GSH via
the sulfhydryl group [5], these results suggest that
arsenic–sulfur single bonds can be formed under
physiological conditions. Investigations into the
competitive interaction between arsenous acid, GSH
(7.5 mM) and the chelating agent DMPS (1.0 mM)
revealed stronger binding of arsenous acid to the
dithiol, DMPS, than to the monothiol, GSH, under
simulated physiological conditions.
Our results regarding the formation of arsenic–
GSH species generally substantiate those obtained by
1
H-NMR. Hence, SEC–GFAAS is an alternative
analytical technique for studying labile associations
between metal / metalloid ions and peptides (GSH)
and chelating agents (DMPS). The simulation of
these reactions at physiologically relevant metal /
metalloid concentrations by SEC–GFAAS, together
with noninvasive 1 H SEFT–NMR spectroscopy,
providing information about the specific binding site,
may be useful for investigating metal / metalloid–
peptide interactions generally.
4. Conclusion
Acknowledgements
SEC in conjunction with GFAAS and using the
‘retention analysis method’ proved to be a useful tool
for studying the dynamic on-column formation of
This work was funded by the Austrian Science
Foundation (FWF), Project number J01303-CHE.
J. Gailer, W. Lindner / J. Chromatogr. B 716 (1998) 83 – 93
References
[1] A. Meister, Glutathione, in I.M. Arias, W.B. Jakoby, H.
Popper, D. Schachter, D.A. Shafritz (Eds.), The Liver:
Biology and Pathobiology, Raven Press, New York, 2nd ed.,
1988, Ch. 23, p. 401
[2] O.W. Griffith, J. Biol. Chem. 256 (1981) 4900.
[3] G. Bellomo, M. Vairetti, L. Stivala, F. Mirabelli, P. Richelmi,
S. Orrenius, Proc. Natl. Acad. Sci. USA 89 (1992) 4412.
[4] N. Kaplowitz, T.Y. Aw, M. Ookhtens, Ann. Rev. Pharmacol.
Toxicol. 25 (1985) 715.
[5] D.L. Rabenstein, Metal complexes of glutathione and their
biological significance, in: D. Dolphin, O. Adamovic, R.
Poulson (Eds.), Glutathione: Chemical, biochemical, and
medical aspects, Part A, Wiley, New York, 1989, Ch. 5, p.
147
[6] M. Delnomdedieu, M.M. Basti, M. Styblo, J.D. Otvos, D.J.
Thomas, Chem. Res. Toxicol. 7 (1994) 621.
[7] R. Mukhopadhyay, S. Dey, N. Xu, D. Gage, J. Lightbody,
M. Oullette, B.P. Rosen, Proc. Natl. Acad. Sci. USA 93
(1996) 10383.
[8] N.T. Christie, M. Costa, Biol. Trace Elem. Res. 6 (1984)
139.
[9] N. Ballatori, T.W. Clarkson, Fund. Appl. Toxicol. 5 (1985)
816.
[10] G.W. Rafter, Biol. Trace Elem. Res. 4 (1982) 191.
[11] M. Styblo, D.J. Thomas, Biochem. Pharmacol. 49 (1995)
971.
[12] M. Styblo, S.V. Serves, W.R. Cullen, D.J. Thomas, Chem.
Res. Toxicol. 10 (1997) 27.
[13] M.G. Cherian, J.J. Vostal, J. Toxicol. Environ. Health 2
(1977) 945.
[14] J. Alexander, J. Aaseth, T. Refsvik, Acta Pharmacol. Toxicol. 49 (1981) 190.
[15] T. Refsvik, T. Norseth, Acta Pharmacol. Toxicol. 36 (1975)
67.
[16] R. Cornelis, F. Borguet, J. de Kimpe, Anal. Chim. Acta 283
(1993) 183.
[17] B. Sebille, N. Thuaud, J. Liq. Chromatogr. 3 (1980) 299.
´ B. Bohs,
¨
[18] J. Oravcova,
W. Lindner, J. Chromatogr. B 677
(1996) 1.
[19] B. Sebille, Fundam. Clin. Pharmacol. 4 (1990) 151s.
[20] D. Chakraborti, K.J. Irgolic, F. Adams, Int. J. Environ. Anal.
Chem. 17 (1984) 241.
93
[21] P.F. Reay, C.J. Asher, Anal. Biochem. 78 (1977) 557.
[22] Y.M. Torchinsky, Reaction of thiols with arsenic compounds,
in Y.M. Torchinsky (Ed.), Sulfur in Proteins, Pergamon
Press, New York, 1981, p. 46
[23] W.R. Cullen, B.C. McBride, J. Reglinski, J. Inorg. Biochem.
21 (1984) 179.
[24] D.C. Spray, R.D. Ginzberg, E.A. Morales, Z. Gatmaitan, I.M.
Arias, J. Cell. Biol. 103 (1986) 135.
[25] D.L. Rabenstein, J. Am. Chem. Soc. 95 (1973) 2797.
[26] N. Scott, K.M. Hatlelid, N.E. MacKenzie, D.E. Carter,
Chem. Res. Toxicol. 6 (1993) 102.
[27] K. Dill, E.R. Adams, R.J. O’Connor, S. Chong, E.L.
McGown, Arch. Biochem. Biophys. 257 (1987) 293.
[28] S.L. Winski, D.E. Carter, J. Toxicol. Environ. Health 46
(1995) 379.
[29] A. Gyurasics, F. Varga, Z. Gregus, Biochem. Pharmacol. 41
(1991) 937.
[30] A. Gyurasics, F. Varga, Z. Gregus, Biochem. Pharmacol. 42
(1991) 465.
¨
[31] I. Anundi, J. Hogberg,
M. Vahter, FEBS Lett. 145 (1982)
285.
[32] T. Ishikawa, Trends Biochem. Sci. 17 (1992) 463.
[33] H. Shen, S. Paul, L.M. Breuninger, P.J. Ciaccio, N.M. Laing,
M. Helt, K.D. Tew, G.D. Kruh, Biochemistry 35 (1996)
5719.
¨
[34] M. Muller,
C. Meijer, G.J.R. Zaman, P. Borst, R.J. Scheper,
N.H. Mulder, E.G.E. de Vries, P.L.M. Jansen, Proc. Natl.
Acad. Sci. USA 91 (1994) 13033.
[35] S. Dey, M. Ouellette, J. Lightbody, B. Papadopoulou, B.
Rosen, Proc. Natl. Acad. Sci. USA 93 (1996) 2192.
[36] M. Delnomdedieu, M.M. Basti, J.D. Otvos, D.J. Thomas,
Chem. Biol. Interact., 90 (1994) 139.
[37] H.V. Aposhian, Annu. Rev. Pharmacol. Toxicol. 23 (1983)
193.
[38] H.V. Aposhian, A. Arroyo, M.E. Cebrian, L.M. Del Razo,
K.M. Hurlbut, R.C. Dart, D. Gonzalez-Ramirez, H. Kreppel,
H. Speisky, A. Smith, M.E. Gonsebatt, P. Ostrosky-Wegman,
M.M. Aposhian, J. Pharmacol. Exp. Ther. 282 (1997) 192.
[39] K. Dill, E.R. Adams, R.J. O’Connor, E.L. McGown, Chem.
Res. Toxicol. 2 (1989) 181.
[40] S. Stocken, R.H.S. Thompson, Biochemistry 40 (1946) 535.
[41] M. Delnomdedieu, M.M. Basti, J.D. Otvos, D.J. Thomas,
Chem. Res. Toxicol. 6 (1993) 598.